Total Synthesis of Laulimalide
no more than three reports from the Ghosh11a and
Nishiyama11d,e groups were available on the synthesis of
major fragments of 1. To date, in addition to an impres-
sive number of 15 approaches to key fragments by several
groups,11 as many as 10 total syntheses of 1 have been
completed.12-16 The first synthesis was accomplished by
Ghosh and Wang,12a,c who later refined their first ap-
proach by a stereoselective introduction of the 2,3-cis-
enoate.12b,c These two reports were followed in close
succession by three syntheses from our group13 and one
from Paterson,14 which all avoid low-yielding protective
group manipulations during the endgame by using a
regio- and stereoselective epoxidation of the unprotected
macrocycle as the last step. This strategy has also been
adopted in the total synthesis by Wender and co-work-
ers,15 which features a diastereoselective Sakurai reaction
for fragment coupling and a regioselective macrolacton-
ization of a 2,3-alkynoic acid with an unprotected vicinal
19,20-diol. Lately, the series of total syntheses of 1 has
been complemented by two closely related approaches
from the Crimmins16a and the Williams16b groups which
both focus on a diastereoselective allylic transfer of a C1-
C14 allylstannane16a (or silane16b) to a C15-C27 R,â-
epoxyaldehyde. A very recent synthesis by Nelson16c is
characterized by extensive use of asymmetric acyl halide-
aldehyde cyclocondensation methodology for the con-
struction of main fragments.
F IGURE 1. Laulimalide (1) and isolaulimalide (2).
analogue of estradiol,10a a combretastatin D analogue,10b
and GS-16410c). However, while the epothilones, disco-
dermolide, and eleutherobin inhibit the binding of [3H]-
paclitaxel to tubulin polymer in a competitive manner,
and thus apparently bind to the same or an overlapping
site at the protein, it was recently discovered3 that
laulimalide binds at a distinct site.
Our interest in laulimalide was kindled in February
1999 by the work of Mooberry and co-workers,2 which
underlined that 1 is as much as 100-fold more potent
than paclitaxel against SKVLB-1 cells, a P-glycoprotein
overexpressing ovarian cancer cell line, which exhibits
multidrug resistance. Very recently, the high therapeutic
potential of 1 was further underlined by Hamel,3 who
found that laulimalide also kills human ovarian carci-
noma cells which, due to taxoid site mutations in the M
40 human â-tubulin gene, are resistant to paclitaxel
(PTX10, PTX22), epothilone A (A8), and epothilone B
(B1).
Apart from the significant clinical potential of 1 and
its restricted natural supply, the attraction of laulimalide
as a synthetic target originates from its unique and
complex molecular architecture. Specifically, its 16,17-
epoxide is susceptible to nucleophilic attack from the 20-
hydroxy group to form the more stable and biologically
less active tetrahydrofuran isomer 2 (Figure 1),1a and the
2,3-cis-enoate moiety readily undergoes Z/E-isomeriza-
tion. When we started our synthetic efforts in late 1999,
Herein, we report the full details of our synthetic
studies, which so far culminated in three total syntheses.
All of them use the same endgame, namely the regio- and
stereoselective epoxidation of 16,17-deoxylaulimalide (3).
In view of the easy isomerization of 1 to 2, we decided to
avoid any protecting group manipulation at the C15- and
C20-OH functions after the introduction of the C16-C17
epoxide17 and to rely on a chirally induced epoxidation18
(11) (a) Ghosh, A. K.; Mathivanan, P.; Cappiello, J . Tetrahedron Lett.
1997, 38, 2427-2430. (b) Ghosh, A. K.; Wang, Y. Tetrahedron Lett.
2000, 41, 2319-2322. (c) Ghosh, A. K.; Wang, Y. Tetrahedron Lett.
2000, 41, 4705-4708. (d) Shimizu, A.; Nishiyama, S. Tetrahedron Lett.
1997, 38, 6011-6014. (e) Shimizu, A.; Nishiyama, S. Synlett 1998,
1209-1210. (f) Mulzer, J .; Hanbauer, M. Tetrahedron Lett. 2000, 41,
33-36. (g) Dorling, E. K.; O¨ hler, E.; Mulzer, J . Tetrahedron Lett. 2000,
41, 6323-6326. (h) Dorling, E. K.; O¨ hler, E.; Mantoulidis, M.; Mulzer,
J . Synlett 2001, 1105-1108. (i) Ahmed, A.; O¨ hler, E.; Mulzer, J .
Synthesis 2001, 2007-2010. (j) Nadolski, G. T.; Davidson B. S.
Tetrahedron Lett. 2001, 42, 797-800. (k) Messenger, B. T.; Davidson
B. S. Tetrahedron Lett. 2001, 42, 801-804. (l) Sivaramakrishnan, A.;
Nadolski, G. T.; McAlexander, I. A.; Davidson B. S. Tetrahedron Lett.
2002, 43, 213-216. (m) Paterson, I.; De Savi, C.; Tudge, M. Org. Lett.
2001, 3, 213-216. (n) Lee, H. W.; J eong, C.-S.; Yoon, S. H.; Lee, I.-Y.
C. Bull. Korean Chem. Soc. 2001, 22, 791-792. (o) Lee, H. W.; Yoon,
S. H.; Lee, I.-Y. C.; Chung, B. Y. Bull. Korean Chem. Soc. 2001, 22,
1179-1180.
(12) (a) Ghosh, A. K.; Wang, Y. J . Am. Chem. Soc. 2000, 122, 11027-
11028. (b) Ghosh, A. K.; Wang, Y. Tetrahedron Lett. 2001, 42, 3399-
3401. (c) Ghosh, A. K.; Wang, Y.; Kim, J . T. J . Org. Chem. 2001, 66,
8973-8982.
(8) (a) Sato, B.; Muramatsu, H.; Miyauchi, M.; Hori, Y.; Takase, S.;
Hino, M.; Hashimoto, S.; Terano, H. J . Antibiot. 2000, 53, 123-130.
(b) Sato, B.; Nakajima, H.; Hori, Y.; Hino, M.; Hashimoto, S.; Terano,
H. J . Antibiot. 2000, 53, 204-206. (c) Yoshimura, S.; Sato, B.;
Kinoshita, T.; Takase, S.; Terano, H. J . Antibiot. 2000, 53, 615-622.
The structure of FR182877 was revised in: J . Antibiot. 2002, 55, C1.
(9) (a) Chen, Z.; Wang, B.; Chen, M. Huaxue Xuebao 1988, 46, 1201-
1206. (b) Kondoh, M.; Usui, T.; Mayumi, T.; Osada, H. J . Antibiot. 1998,
51, 801-804. (c) Roux, D.; Hadi, H. A.; Thoret, S.; Guenard, D.;
Thoison, O.; Paies, M.; Sevenet, T. J . Nat. Prod. 2000, 63, 1070-1076.
(10) (a) Wang, Z.; Yang, D.; Mohanakrishnan, A. K.; Fanwick, P.
E.; Nampoothiri, P.; Hamel, E.; Cushman, M. J . Med. Chem. 2000,
43, 2419-2429. (b) Couladouros, E. A.; Li, T.; Moutsos, V. I.; Pitsinos,
E. N.; Soufli, I. C. Bioorg. Med. Chem. Lett. 1999, 9, 2927-2928. (c)
Shintani, Y.; Tanaka, T.; Nozaki, Y. Cancer Chemother. Pharmacol.
1997, 40, 513-520.
(13) (a) Mulzer, J .; O¨ hler, E. Angew. Chem., Int. Ed. 2001, 40, 3842-
3846. (b) Enev, V. E.; Ka¨hlig, H.; Mulzer, J . J . Am. Chem. Soc. 2001,
123, 10764-10765. (c) Mulzer, J .; Hanbauer, M. Tetrahedron Lett.
2002, 43, 3381-3383.
(14) Paterson, I.; De Savi, C.; Tudge, M. Org. Lett. 2001, 3, 3149-
3152.
(15) Wender, P. A.; Hegde, S. G.; Hubbard, R. D.; Zhang, L. J . Am.
Chem. Soc. 2002, 124, 4956-4957.
(16) (a) Crimmins, M. T.; Stanton, M. G.; Allwein, S. P. J . Am. Chem.
Soc. 2002, 124, 5958-5959. (b) Williams, D. R.; Mi, L.; Mullins, R. J .;
Stites, R. E. Tetrahedron Lett. 2002, 43, 4841-4844. (c) Nelson, S. G.;
Cheung, W. S.; Kassick, A. J .; Hilfiker, M. A. J . Am. Chem. Soc. 2002,
124, 13654-13655.
(17) The recent work of Crimmins16a revealed that removal of two
TBS protecting groups from the C15 and C20 hydroxyls is possible
without rearrangement to isolaulimalide (2).
J . Org. Chem, Vol. 68, No. 8, 2003 3027